Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease.
Apomorphine in combination with a peripheral dopamine receptor blocker (domeperidone) was administered to four parkinsonian patients in a double-blind placebo-controlled study. The therapeutic efficacy of apomorphine was not reduced by domperidone, while nausea, drowsiness, sedation, and arterial hypotension were prevented. Combination of domperidone with dopamine agonists may result in more effective treatment of Parkinson's disease.
D001058:Apomorphine / Q000008:administration & dosage*; D001562:Benzimidazoles / Q000008:administration & dosage*; D001812:Blood-Brain Barrier / Q000187:drug effects; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D010880:Piperidines / Q000008:administration & dosage*; D010919:Placebos; D011954:Receptors, Dopamine / Q000187:drug effects*
D001562:Benzimidazoles; D010880:Piperidines; D010919:Placebos; D011954:Receptors, Dopamine; D001058:Apomorphine